why choose us

First received: November 29, 2023

Clinical Trial: A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Persistent Infection

Study Type: INTERVENTIONAL


Official Title: A Phase 1b/2a Study To Evaluate The Safety Of CMTX-101 In Combination With Inhaled Antibiotics In People With Cystic Fibrosis Chronically Infected With Pseudomonas Aeruginosa

Brief Summary: CMTX-101 is a bacterial biofilm disrupting monoclonal antibody being developed as an adjunctive therapy to standard of care antibiotics.The goal of this clinical trial is to assess the safety and tolerability of CMTX-101 in people with cystic fibrosis (pwCF).The main questions the study aims to answer are:Are single doses of CMTX-101 IV infusion safe and toleratedWhat is the pharmacokinetic (PK) profile of single doses of CMTX-101Do single doses of CMTX-101 induce development of anti-drug antibodies (ADA) and…

Read more